Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways

Annual Review of Immunology

Volumn 25, Issue , 2007, Pages 101-137

  Serhan, Charles N ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Anti inflammatories; Aspirin; DHA; EPA; Human leukocytes; Omega 3 PUFA

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; AUTACOID; CD59 ANTIGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; INDOMETACIN; LIPID; LIPOXIN; OMEGA 3 FATTY ACID; PROSTAGLANDIN E2; RESOLVIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; ENZYME INACTIVATION; EPIMER; EPOXIDATION; HUMAN; INFLAMMATION; LEUKOCYTE; LIPID METABOLISM; LIPOGENESIS; NEUROPROTECTION; NONHUMAN; PERITONITIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PUS; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOXINS; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 34247847681     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.25.022106.141647     Document Type: Review

References (172)

1. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192:1197-204
2. Gilroy DW, Lawrence T, Perretti M, Rossi AG. 2004. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3:401-16
3. Serhan CN. 1994. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212:1-25
4. Funk CD. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871-75
5. Serhan CN, ed. 2005. Special Issue on Lipoxins and Aspirin-Triggered Lipoxins. Prostaglandins Leukotrienes Essent. Fat. Acids 73:(3-4)
6. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, et al. 2005. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201:713-22
7. Hong S, Gronert K, Devchand P, Moussignac R-L, Serhan CN. 2003. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem. 278:14677-87
8. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, et al. 2006. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176:1848-59
9. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, et al. 2002. Resolvins: a family of bioacdve products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196:1025-37.
10. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:612-19
11. Cotran RS, Kumar V, Collins T, ed. 1999. Robbins Pathologic Basis of Disease. Philadelphia: Saunders. 1425 pp.
12. Majno G, Joris I. 2004. Cells, Tissues, and Disease: Principles of General Pathology. New York: Oxford Univ. Press. 1005 pp.
13. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, et al. 2005. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174:4345-55
14. Serhan CN, Savill J. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6:1191-97
15. Marcheselli VL, Hong S, Lukiw WJ, Hua Tian X, Gronert K, et al. 2003. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and proinflammatory gene expression. J. Biol. Chem. 278:43807-17
16. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, et al. 2005. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115:2774-83
17. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. 2004. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 101:8491-96
18. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Schwartzman ML. 2005. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280:15267-78
19. Calder PC. 2004. n-3 fatty acids and inflammation - new twists on an old tale. PUFA Newsl. 8(3) http.//www.fatsoflife.com/pufa/pdf/pufa0904. pdf
20. De Caterina R, Endres S, Kristensen SD, Schmidt EB, ed. 1993. n-3 Fatty Acids and Vascular Disease. London: Springer-Verlag
21. Hong S, Tjonahen E, Morgan EL, Yu L, Serhan CN, Rowley AF. 2005. Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins - mediator lipidomic analysis. Prostaglandins Other Lipid Mediat. 78:107-16
22. Lands WEM, ed. 1987. Proceedings of the AOCS Short Course on Polyunsaturated Fatty Acids and Eicosanoids. Champaign, IL: Am. Oil Chem. Soc.
23. Prescott SM, Stenson WF. 2005. Fish oil fix. Nat. Med. 11:596-98
24. Hansson G, Robertson AKL, Soderberg-Naucler C. 2006. Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis. 1:297-329
25. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. 2004. C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585-90
26. Nathan C. 2002. Points of control in inflammation. Nature 420:846-52
27. Van Dyke TE, Serhan CN. 2003. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 82:82-90
28. Cotran RS, Kumar V, Collins T. 1999. Cellular pathology I: cell injury and cell death. See Ref. 11, pp. 1-29
29. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:698-701
30. Majno G. 1975. The Healing Hand: Man and Wound in the Ancient World. Cambridge: Harvard Univ. Press
31. Dale HH. 1965. Pharmacology during the past sixty years. In The Excitement and Fascination of Science: A Collection of Autobiographical and Philosophical Essays, ed. JM Luck, 1:75-82. Palo Alto, CA: Annual Reviews
32. von Euler US. 1978. Pieces in the puzzle. In The Excitement and Fascination of Science: Reflections by Eminent Scientists, ed. WC Gibson, 2:675-86. Palo Alto, CA: Annual Reviews
33. Samuelsson B. 1982. From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures, pp. 153-74. Stockholm: Almqvist & Wiksell
34. Tauber AI, Chernyak L. 1991. Metchnikoff and the Origins of Immunology: From Metaphor to Theory. New York: Oxford Univ. Press. 247 pp.
35. Serhan CN. 2004. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem. Cell Biol. 122:305-21
36. Samuelsson B. 1983. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-75
37. Burr GO, Burr MM. 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 82:345-67
38. Bazan NG. 1990. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In Nutrition and the Brain, ed. RJ Wurtman, JJ Wurtman, pp. 1-22. New York: Raven
39. Simopoulos AP, Leaf A, Salem N Jr. 1999. Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. J. Am. Coll. Nutr. 18:487-89
40. Salem N Jr, Litman B, Kim H-Y, Gawrisch K. 2001. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36:945-59
41. Vane JR. 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures, pp. 181-206. Stockholm: Almqvist & Wiksell
42. Bergström S. 1982. The prostaglandins: from the laboratory to the clinic. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures, pp. 129-48. Stockholm: Almqvist & Wiksell
43. Borgeat P, Samuelsson B. 1979. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc. Natl. Acad. Sci. USA 76:2148-52
44. Cassatella MA, ed. 2003. The Neutrophil. Basel: Karger
45. Gilroy DW, Perretti M. 2005. Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Curr. Opin. Pharmacol. 5:405-11
46. Meiler SE, Fleisher LA, ed. 2006. Influence of Perioperative Care on Outcome. Philadelphia: Saunders
47. Gallin JI, Snyderman R, Fearon DT, Haynes BF, Nathan C, ed. 1999. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippincott. 1360 pp.
48. Lawrence T, Willoughby DA, Gilroy DW. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2:787-95
49. Serhan CN. 2005. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukotrienes Essent. Fat. Acids 73:141-62
50. Serhan CN, Hamberg M, Samuelsson B. 1984. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 81:5335-39
51. Chiang N, Arita M, Serhan CN. 2005. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor. Prostaglandins Leukotrienes Essent. Fatty Acids 73:163-77
52. Pettitt TR, Rowley AF, Barrow SE, Mallet AI, Secombes CJ. 1991. Synthesis of lipoxins and other lipoxygenase products by macrophages from the rainbow trout, Oncorhynchus mykiss. J. Biol. Chem. 266:8720-26
53. Rowley AF. 1991. Lipoxin formation in fish leucocytes. Biochim. Biophys. Acta 1084:303-6
54. Rowley AF, Lloyd-Evans P, Barrow SE, Serhan CN. 1994. Lipoxin biosynthesis by trout macrophages involves the formation of epoxide intermediates. Biochemistry 33:856-63
55. Menezes-de-Lima O Jr, Kassuya CA, Nascimento AF, Henriques MG, Calixto JB. 2006. Lipoxin A4 inhibits edema in mice: implications for the anti-edematogenic mechanism induced by aspirin. Prostaglandins Other Lipid Mediat. 80:123-35
56. Maddox JF, Serhan CN. 1996. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183:137-46
57. Hachicha M, Pouliot M, Petasis NA, Serhan CN. 1999. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189:1923-29
58. Maderna P, Yona S, Perretti M, Godson C. 2005. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J. Immunol. 174:3727-33
59. Gronert K, Gewirtz A, Madara JL, Serhan CN. 1998. Identification of a human enterocyte lipoxin A4 receptor that is regulated by IL-13 and IFN-γ and inhibits TNF-α-induced IL-8 release. J. Exp. Med. 187:1285-94
60. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN. 1993. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 92:1572-79
61. Edenius C, Kumlin M, Bjork T, Anggard A, Lindgren JA. 1990. Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett. 272:25-28
62. Serhan CN, Sheppard KA. 1990. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Invest. 85:772-80
63. Lindstrom P, Lerner R, Palmblad J, Patarroyo M. 1990. Rapid adhesive responses of endothelial cells and of neutrophils induced by leukotriene B4 are mediated by leukocytic adhesion protein CD18. Scand. J. Immunol. 31:737-44
64. Romano M, Serhan CN. 1992. Lipoxin generation by permeabilized human platelets. Biochemistry 31:8269-77
65. Fiore S, Maddox JF, Perez HD, Serhan CN. 1994. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180:253-60
66. Brezinski ME, Serhan CN. 1990. Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc. Natl. Acad. Sci. USA 87:6248-52
67. Clària J, Serhan CN. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92:9475-79
68. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. 2004. Aspirin triggers anti-inflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101:15178-83
69. Chiang N, Hurwitz S, Ridker PM, Serhan CN. 2006. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol. 26:14-17
70. Fiorucci S, Di Lorenzo A, Renga B, Farneti S, Morelli A, Cirino G. 2004. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2- naphthaleneacetic acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J. Pharmacol. Exp. Ther. 311:1264-71
71. von der Weid PY, Hollenberg MD, Fiorucci S, Wallace JL. 2004. Aspirin-triggered, cyclooyxgenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 110:1320-25
72. Serhan CN. 2004. U.S. Patent No. 2004/0116408 A1
73. Serhan CN, Clish CB. 2003. U.S. Patent No. 6,670,396 B2
74. Serhan CN, Fiore S, Brezinski DA, Lynch S. 1993. Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry 32:6313-19
75. Serhan CN, Maddox JF, Petasis NA, Akritopoulou-Zanze I, Papayianni A, et al. 1995. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34:14609-15
76. Rodgers K, McMahon B, Mitchell D, Sadlier D, Godson C. 2005. Lipoxin A4 modifies platelet-derived growth factor-induced profibrotic gene expression in human renal mesangial cells. Am. J. Pathol. 167:683-94
77. Kieran NE, Maderna P, Godson C. 2004. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65:1145-54
78. Sato Y, Kitasato H, Murakami Y, Hashimoto A, Endo H, et al. 2004. Down-regulation of lipoxin A4 receptor by thromboxane A2 signaling in RAW246.7 cells in vitro and bleomycin-induced lung fibrosis in vivo. Biomed. Pharmacother. 58:381-87
79. Wu SH, Wu XH, Lu C, Dong L, Chen ZQ. 2006. Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. Am. J. Respir. Cell Mol. Biol. 34:65-72
80. Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, et al. 2004. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. USA 101:15736-41
81. Guilford WJ, Bauman JG, Skuballa W, Bauer S, Wei GP, et al. 2004. Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J. Med. Chem. 47:2157-65
82. Serhan CN. 2002. Endogenous chemical mediators in anti-inflammation and proresolution. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents 1:177-92
83. Clish CB, Levy BD, Chiang N, Tai H-H, Serhan CN. 2000. Oxidoreductases in lipoxin A4 metabolic inactivation. J. Biol. Chem. 275:25372-80
84. Clish CB, O'Brien JA, Gronert K, Stahl GL, Petasis NA, Serhan CN. 1999. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA 96:8247-52
85. Levy BD, Fokin VV, Clark JM, Wakelam MJO, Petasis NA, Serhan CN. 1999. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a "stop" signaling switch for aspirin-triggered lipoxin A4. FASEB J. 13:903-11
86. Ohira T, Bannenberg G, Arita M, Takahashi M, Ge Q, et al. 2004. A stable aspirin-triggered lipoxin A4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J. Immunol. 173:2091-98
87. Perretti M, Chiang N, La M, Fierro IM, Marullo S, et al. 2002. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8:1296-302
88. Chiang N, Serhan CN, Dahlén S-E, Drazen JM, Hay DWP, et al. 2006. International Union of Pharmacology. The lipoxin receptor ALX: potent ligand specific and stereoselective actions in vivo. Pharmacol. Rev. 58:463-87
89. Brink C, Dahlén S-E, Drazen J, Evans JF, Hay DWP, et al. 2003. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55:195-227
90. Bürli RW, Xu H, Zou X, Muller K, Golden J, et al. 2006. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett. 16:3713-18
91. Kenakin T. 2005. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4:919-27
92. Wallace JL, Fiorucci S. 2003. Amagic bullet for mucosal protection...and aspirin is the trigger! Trends Pharmacol. Sci. 24:323-26
93. Fiorucci S, Santucci L, Wallace JL, Sardina M, Romano M, et al. 2003. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc. Natl. Acad. Sci. USA 100:10937-41
94. Petasis NA, Akritopoulou-Zanze I, Fokin VV, Bernasconi G, Keledjian R, et al. 2005. Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukotrienes Essent. Fat. Acids 73:301-21
95. Andersson P, Serhan CN, Petasis NA, Palmblad J. 2004. Interactions between lipoxin A4, the stable analogue 16-phenoxy-lipoxin A4 and leukotriene B4 in cytokine generation by human monocytes. Scand. J. Immunol. 60:249-56
96. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. 2002. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. USA 99:13266-71
97. Flower RJ. 2003. The development of COX2 inhibitors. Nat. Rev. Drug Discov. 2:179-91
98. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Villela CG, Fierro IM. 2005. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am. J Physiol. Cell Physiol. 289:C557-63
99. Paul-Clark MJ, van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 2004. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200:69-78
100. Fiorucci S, Distrutti E, Mencarelli A, Rizzo G, Di Lorenzo AR, et al. 2004. Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of NCX-4016 (NO-aspirin) on neutrophil-endothelial cell adherence. J. Pharmacol. Exp. Ther. 309:1174-82
101. Weissmann G, Smolen JE, Korchak HM. 1980. Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 303:27-34
102. 4, is protective in experimental ischemic acute renal failure. J. Am. Soc. Nephrol. 13:1657-62
103. 4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. Kidney Int. 69:248-56
104. Heasman SJ, Giles KM, Ward C, Rossi AG, Haslett C, Dransfield I. 2003. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J. Endocrinol. 178:29-36
105. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. 2000. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164:1663-67
106. Brady HR, Papayianni A, Serhan CN. 1995. Potential vascular roles for lipoxins in the "stop programs" of host defense and inflammation. Trends Cardiovasc. Med. 5:186-92
107. 4 stable analogs are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185:1693-704
108. Yopp AC, Randolph GJ, Bromberg JS. 2003. Leukotrienes, sphingolipids, and leukocyte trafficking. J. Immunol. 171:5-10
109. Lu Y, Hong S, Tjonahen E, Serhan CN. 2005. Mediator-lipidomics: databases and search algorithms for PUFA-derived mediators. J. Lipid Res. 46:790-802
110. Williams TJ, Peck MJ. 1977. Role of prostaglandin-mediated vasodilatation in inflammation. Nature 270:530-32
111. Pouliot M, Fiset ME, Masse M, Naccache PH, Borgeat P. 2002. Adenosine up-regulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. J. Immunol. 169:5279-86
112. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104:309-16
113. 4 stable analogues. J. Clin. Invest. 101:819-26
114. 4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 92:75-82
115. Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P. 2002. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med. 165:1531-35
116. 4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168:5260-67
117. 4 counteracts synergistic activation of human fibroblast-like synoviocytes. Int. J. Immunopathol. Pharmacol. 17:15-25
118. 4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol. 164:2660-66
119. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. 2005. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434:1138-43
120. Emerson MR, LeVine SM. 2004. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res. 1021:140-45
121. Bafica A, Scanga CA, Serhan C, Machado F, White S, et al. 2005. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Invest. 115:1601-6
122. GISSI-Prevenzione Investigators. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354:447-55
123. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, et al. 2002. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897-903
124. Bazan NG. 1992. Supply, uptake, and utilization of docosahexaenoic acid during photoreceptor cell differentiation. Nestle Nutr. Workshop Ser. 28:121-33
125. Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K, Chiang N. 2000. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J. Physiol. Pharmacol. 51:643-54
126. Winyard PG, Willoughby DA, ed. 2003. Inflammation Protocols. Totowa, NJ: Humana. 378 pp.
127. Lu Y, Hong S, Gotlinger K, Serhan CN. 2006. Lipid mediator informatics and proteomics in inflammation-resolution. Sci. World J. 6:589-614
128. Tjonahen E, Oh S, Siegelman J, Elangovan S, Percarpio K, et al. 2006. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13:1193-202
129. Bazan NG, Birkle DL, Reddy TS. 1984. Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina. Biochem. Biophys. Res. Commun. 125:741-47
130. Morrow JD, Roberts LJ. 1997. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36:1-21
131. VanRollins M, Baker RC, Sprecher HW, Murphy RC. 1984. Oxidation of docosahexaenoic acid by rat liver microsomes. J. Biol. Chem. 259:5776-83
132. Sawazaki S, Salem N Jr, Kim H-Y. 1994. Lipoxygenation of docosahexaenoic acid by the rat pineal body. J. Neurochem. 62:2437-47
133. Bazan NG. 2006. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 29:263-71
134. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, et al. 2006. RvE1 protects from local inflammation and osteoclast mediated bone destruction in periodontitis. FASEB J. 20:401-3
135. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, et al. 2005. Resolvin E1, a novel endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against TNBS-induced colitis. Proc. Natl Acad. Sci. USA 102:7671-76
136. Arita M, Oh S, Chonan T, Hong S, Elangovan S, et al. 2006. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281:22847-54
137. Serhan CN. 2006. Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol. Clin. N. Am. 24:341-64
138. Karp CL, Cooper AM. 2005. An oily, sustained counter-regulatory response to TB. J. Clin. Invest. 115:1473-76
139. Weylandt KH, Kang JX. 2005. Rethinking lipid mediators. Lancet 366:618-20
140. 4 induces heme oxygenase-1 in endothelial cells." Am. J. Physiol. Cell Physiol. 289:507-8
141. Damazo AS, Yona S, Flower RJ, Perretti M, Oliani SM. 2006. Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J. Immunol. 176:4410-18
142. Rowlinson SW, Crews BC, Goodwin DC, Schneider C, Gierse JK, Marnett LJ. 2000. Spatial requirements for 15-(R)-hydroxy-5Z,8Z, 11Z,13E- eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. J. Biol. Chem. 275:6586-91
143. Xiao G, Tsai A-L, Palmer G, Boyar WC, Marshall PJ, Kulmacz RJ. 1997. Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2. Biochemistry 36:1836-45
144. 4 levels. Exp. Gerontol. 40:612-14
145. Aliberti J, Hieny S, Reis e Sousa C, Serhan CN, Sher A. 2002. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3:76-82
146. 4 analogs block extracellular signal-regulated kinase-dependent TNF-α secretion from human T cells. J. Immunol. 170:6266-72
147. Arita M, Clish CB, Serhan CN. 2005. The contributions of aspirin and microbial oxygenase in the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem. Biophys. Res. Commun. 338:149-57
148. Serhan CN, Arita M, Hong S, Gotlinger K. 2004. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 39:1125-32
149. Rodriguez AR, Spur BW. 2004. First total synthesis of 7(S),16(R),17(S)-resolvin D2, a potent anti-inflammatory lipid mediator. Tetrahedron Lett. 45:8717-20
150. 4 stable analog displays a unique topical anti-inflammatory profile. J. Immunol. 169:7063-70
151. 4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc. Natl. Acad. Sci. USA 94:9967-72
152. 4. J. Pharmacol. Exp. Ther. 300:385-92
153. 4. Impact of aspirin therapy. Circulation 86:56-63
154. Mangino MJ, Brounts L, Harms B, Heise C. 2006. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 79:84-92
155. Stenke L, Mansour M, Edenius C, Reizenstein P, Lindgren JA. 1991. Formation and proliferative effects of lipoxins in human bone marrow. Biochem. Biophys. Res. Commun. 180:255-61
156. Stenke L, Edenius C, Samuelsson J, Lindgren JA. 1991. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 78:2989-95
157. Stenke L, Nasman-Glaser B, Edenius C, Samuelsson J, Palmblad J, Lindgren JA. 1991. Lipoxygenase products in myeloproliferative disorders: increased leukotriene C4 and decreased lipoxin formation in chronic myeloid leukemia. Adv. Prostaglandin Thromboxane Leukotriene Res. 21B:883-86
158. Munger KA, Montero A, Fukunaga M, Uda S, Yura T, et al. 1999. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. USA 96:13375-80
159. 4 block allergen-induced eosinophil trafficking. J. Immunol. 164:2267-71
160. 4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 164:1029-36
161. 4. Nat. Med. 8:1018-23
162. Karp CL, Flick LM, Park KW, Softic S, Greer TM, et al. 2004. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5:388-92
163. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, et al. 2003. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171:6856-65
164. 4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: A role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39:4761-68
165. Cotran PR, Hsu C, Serhan CN. 1995. Lipoxin derivatives reduce intraocular pressure in rabbits. Presented at Assoc. Res. Vision Ophthalmol., Ft. Lauderdale, FL
166. 4 in chronic mastitis-affected cows. J. Dairy Sci. 86:3430-39
167. Devchand PR, Schmidt BA, Primo VC, Zhang Q-y, Arnaout MA, et al. 2005. A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils. FASEB J. 19:203-10
168. Hong S, Lu Y, Duffield JS, Vaidya VS, Fredman G, et al. 2005. Mediator-lipidomics for ischemic acute renal failure: biosynthesis and
169. Hudert CA, Weylandt KH, Wang J, Lu Y, Hong S, et al. 2006. Transgenic mice rich in endogenous n-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA 103:11276-81
170. González-Périz A, Planagumà A, Gronert K, Miquel R, López-Parra M, et al. 2006. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 20:2537-39
171. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, et al. 2007. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 178:496-502
172. H2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280:43079-86